Meet the new Business Development Team
Meet Intravacc’s new Business Development Team. A team of experienced professionals, dedicated to the success of your project.
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands) The Hague, The Netherlands, 3 May 2023 – The State of the Netherlands, the Dutch Ministry of Health, Welfare and Sport today announces its intentions to sell 100% of the issued and outstanding shares in the capital of Intravacc B.V. through a controlled auction process.…
Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow
Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology and adjuvants Bilthoven, The Netherlands, 23 February 2023 – Intravacc, a world leader in…
Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®
• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection
• Global incidence rate of this sexual transmitted disease is at 87 million infections per year
• OMV technology is a powerful tool to induce protective systemic and mucosal immunity
• Data published in the peer reviewed journal MSphere of the American Society of Microbiology
Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2
Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it enrolled the first participant in a phase I first in-human clinical trial of Avacc…
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee Bilthoven, The Netherlands, 6 October 2022 – CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI’s US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2…
Intravacc awarded US$14.6 Million NIH/NIAID contract to develop Intranasal Gonorrhea vaccine
Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine Bilthoven, The Netherlands, 5 October 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a contract with base and options that may total US$14.6 million from the US National Institute…
Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine
Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company’s SARS-CoV-2 intranasal candidate vaccine. These results…
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the German Center for Neurogenerative Diseases (DZNE), have been awarded a funding of € 2.5 million…
